4D Molecular Therapeutics (FDMT) Insider Gray Buys 50,000 Shares

On June 17, 2026, Susannah Gray acquired 50,000 shares of 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT). This insider purchase did not specify a transaction value or average price, but it reflects a notable interest in the company's future prospects.

Insider Buying and Selling at 4D Molecular Therapeutics, Inc.

Several insiders, including Susannah Gray, made significant purchases on June 17, 2026. Charles Theuer, Glenn Sblendorio, John Milligan, Jacob Chacko, and Nancy Miller-Rich each bought 50,000 shares, while John Milligan acquired 75,000 shares. These transactions were not part of a pre-planned trading program.

4D Molecular Therapeutics, Inc. Stock Down 36.5%

Shares of 4D Molecular Therapeutics traded at $9.66. The company has a market capitalization of approximately $505 million and a beta of 2.756, indicating higher volatility compared to the market. The stock's 52-week range spans from $3.68 to $12.34, with a 50-day moving average of $9.43 and a 200-day moving average of $9.24. The company is not currently profitable, with a forward P/E ratio not meaningful due to negative earnings per share.

Analysts Set New Price Targets

Analysts remain optimistic about 4D Molecular Therapeutics, with Jefferies assuming coverage with a 'buy' rating and a $21.00 price target on March 30, 2026. HC Wainwright & Co. reiterated their 'buy' rating with a $36.00 target on March 20, 2026, and RBC Capital maintained a 'buy' rating with a $35.00 target on March 19, 2026. The consensus among analysts is a 'buy' rating, with a mean price target of $28.22 across nine opinions.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc. is a biotechnology company based in Emeryville, California, specializing in developing adeno-associated virus vectors. These vectors are used in gene therapy applications, with its lead product candidate, 4D-150, targeting retinal vascular diseases. The company also has projects in cystic fibrosis, geographic atrophy, and alpha-1 anti-trypsin deficiency lung disease. Founded in 2013, 4D Molecular Therapeutics collaborates with Otsuka Pharmaceutical Co., Ltd.

Bottom Line

The recent insider purchases by Susannah Gray and other executives at 4D Molecular Therapeutics underscore their confidence in the company's potential. As a late-stage biotech firm, 4D Molecular Therapeutics is focused on innovative gene therapy solutions, which could drive future growth. Investors often track such insider activities for insights, though it's essential to remember that these transactions may not reflect the company's current financial position or future stock performance.